Gene Editing Market

Gene Editing Market by Product & Service (Reagents, Consumables, Systems, Software), Technology (CRISPR, TALEN, ZFN, Antisense), Application (Cell Line Engineering, Genetic Engineering, Drug Discovery), End User (Pharma, Biotech) Global Forecast to 2028

Report Code: BT 3380 Jul, 2023, by marketsandmarkets.com

The global gene editing market in terms of revenue was estimated to be worth $5.3 billion in 2023 and is poised to reach $10.6 billion by 2028, growing at a CAGR of 15.0% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The key driving factors of the market include rising government funding and the number of genomics projects, growing applications of genomics, and introduction of CRISPR-Cas9. Whereas Extensive use of genome editing in personalized medicine and expanding pipeline for gene therapy are anticipated to create lucrative opportunities for players operational in market. However, off-target effects of CRISPR technology are expected to restrain market growth. Presently, high equipment costs pose a challenge to the professionals operating in this market. Introduction of affordable products/equipment is expected to mitigate the impact of this challenge.

Attractive Opportunities in the Gene Editing Market

Gene Editing Market

To know about the assumptions considered for the study, Request for Free Sample Report

Gene Editing Market

Gene Editing Market Dynamics

DRIVER: Growing applications of genomics

Future trends in genomic engineering include its use in marine engineering for applications such as developing nutraceuticals from algae. Forensic sciences and personalized medicine are some of the other upcoming application areas. NGS can be used for DNA barcoding to identify fish larvae and eggs, along with the complete description of fish communities while assessing fish populations. Genomics is increasingly being used in food quality and safety testing. Genome editing technologies are vital in drug discovery and diagnosing and treating human genetic disorders. Genome editing is also used in NGS, DNA analysis & profiling, and plant and animal genetic engineering. Thus, with the growing application areas of genomics, the demand for genome editing technologies is expected to increase during the forecast period.

RESTRAINT: Off-target effects of CRISPR technology

The off-target effects of CRISPR technology pose a significant restraint in gene editing. While CRISPR-Cas9 offers remarkable precision in targeting specific genes, it can also result in unintended modifications at sites other than the intended target. This off-target activity can lead to potential risks and challenges in applying CRISPR technology. Ensuring accurate targeting is crucial to minimize the risk of unintended modifications and potential adverse effects. Researchers are refining CRISPR techniques and developing strategies to improve specificity and reduce off-target effects. Advancements such as high-fidelity Cas9 variants, improved guide RNA design, and bioinformatics tools have shown promise in mitigating off-target activity.

OPPORTUNITY: Expanding pipeline for gene therapy

The expanding pipeline for gene therapy in the gene editing industry presents significant opportunities for advancements in treating genetic disorders and other diseases. Gene therapy involves the delivery of therapeutic genes or gene editing tools into the patient’s cells to correct genetic mutations, restore normal gene function, or introduce therapeutic genes for targeted treatment. The growing number of gene therapy candidates in the development pipeline highlights the potential for transformative breakthroughs in personalized medicine and the treatment of previously incurable diseases.

CHALLENGE: High equipment costs

The costs associated with gene editing equipment can be substantial. For instance, gene editing technologies like CRISPR-Cas9 require specialized laboratory equipment, including DNA sequencers, thermal cyclers, electroporation devices, and fluorescence microscopes. These instruments can have high price tags, ranging from thousands to millions of dollars. In addition to equipment costs, procuring quality reagents, such as nucleases, guide RNAs, and donor templates, can contribute to the overall expenses.

Gene Editing Market Ecosystem

R&D is the initial stage in the value chain of the market. Extensive R&D is required to develop these products. R&D activities are divided into in-house and outsourced tasks. In-house tasks focus on critical activities that deal with fundamental analysis and the electronic interpretation of testing parameters. Prominent companies providing gene editing products & services, SMEs, distributors, and end customers (pharmaceutical & biotechnology companies, academic & research institutions, and diagnostic companies) are the key stakeholders in the supply chain of the gene editing industry. Investors/funders are the major influencers in the market.

The prominent players in the global gene editing market are Merck KGaA (Germany), Thermo Fisher Scientific, Inc. (US), GenScript (China), Agilent Technologies (US), PerkinElmer (US), Lonza (Switzerland), Tecan Life Sciences (Switzerland), Sangamo Therapeutics (US), Editas Medicine (US), CRISPR Therapeutics AG (Switzerland), Precision Biosciences (US), Cellectis S.A. (France), Intellia Therapeutics (US), Bluebird Bio, Inc. (US), Regeneron Pharmaceuticals (US), AMSBIO (England), Creative Biogene (US), Synthego Corporation (US), and Beam Therapeutics Inc. (US). Others include Caribou Biosciences, Inc. (US), OriGene Technologies (US), New England Biolabs (US), Inscripta (US), and Mammoth Biosciences (US).

Ecosystem Analysis: Gene Editing Market

Gene Editing Market Ecosystem

Source: Annual Reports, SEC Filings, Investor Presentations, Expert Interviews, and MarketsandMarkets Analysis

Based on product & service, reagents & consumables segment accounted for the largest share of the gene editing industry in 2022

Based on product & service, the gene editing market is segmented into reagents & consumables, software & systems, and services. The reagents & consumables segment accounted for the largest share in 2022. Reagents and consumables include various products, such as library preparation, purification, and target enrichment kits; plates; chips; tube strips; foil seals; plate holders; and slide holders. The growing applications of genomics in various fields are expected to boost the consumables market. Advancements in library preparation technologies have also enabled the use of NGS in epigenetics and transcriptomics. These kits are used in sequencing applications, such as whole-genome and targeted DNA sequencing.

Based on technology, CRISPR segment accounted for the largest share of the gene editing industry in 2022

Based on technology, the gene editing market is segmented into TALEN, CRISPR, antisense, ZFN, and other technologies. The CRISPR segment dominated the market with the highest share of in 2022. CRISPR-Clustered Regularly Interspaced Short Palindromic Repeats has emerged as a pivotal tool for gene editing as an alternative to traditional genetic modification techniques. Cas9 enzymes differentiate CRISPR from other forms of genetic modification. CRISPR edits and rearranges genes by cutting out the damaged or unwanted part of the DNA, allowing the remaining DNA to be rearranged in a new way.

The North America region is projected to contribute the largest share for the gene editing industry.

The global gene editing market is segmented into five major regions—North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America is the largest regional market for gene editing. US has emerged as the key revenue contributor to this region. The gene editing space has attracted significant investments and funding from venture capitalists, government agencies, and private entities in the US. This funding has fueled R&D efforts and the translation of gene editing technologies into commercial applications. The availability of capital has facilitated the growth of gene editing companies and the advancement of therapeutic interventions.

Gene Editing Market by Region

To know about the assumptions considered for the study, download the pdf brochure

The global gene editing market is a fragmented market, with Merck KGaA (Germany), Thermo Fisher Scientific, Inc. (US), GenScript (China) emerging as the top 3 players of the global market. Players such as Agilent Technologies (US), PerkinElmer (US), Lonza (Switzerland), Tecan Life Sciences (Switzerland), Sangamo Therapeutics (US), Editas Medicine (US), CRISPR Therapeutics AG (Switzerland), Precision Biosciences (US), Cellectis S.A. (France), Intellia Therapeutics (US), Bluebird Bio, Inc. (US), Regeneron Pharmaceuticals (US), AMSBIO (England), Creative Biogene (US), Synthego Corporation (US), and Beam Therapeutics Inc. (US). Others include Caribou Biosciences, Inc. (US), OriGene Technologies (US), New England Biolabs (US), Inscripta (US), and Mammoth Biosciences (US) are some of the prominent players in the market.

Get online access to the report on the World's First Market Intelligence Cloud

  • Easy to Download Historical Data & Forecast Numbers
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
Request Sample

Scope of the Report

Report Metric 

Details 

Market Size Available for Years

2021–2028

Base Year Considered

2022

Forecast Period

2023–2028

Forecast Units

Value (USD Million/Billion)

Segments Covered

Product & Service, Technology, Application, End User, And Region

Geographies Covered

North America, Europe, Asia Pacific, Latin America and MEA

Companies Covered

Merck KGaA (Germany), Thermo Fisher Scientific, Inc. (US), GenScript (China), Agilent Technologies (US), PerkinElmer (US), Lonza (Switzerland), Tecan Life Sciences (Switzerland), Sangamo Therapeutics (US), Editas Medicine (US), CRISPR Therapeutics AG (Switzerland), Precision Biosciences (US), Cellectis S.A. (France), Intellia Therapeutics (US), Bluebird Bio, Inc. (US), Regeneron Pharmaceuticals (US), AMSBIO (England), Creative Biogene (US), Synthego Corporation (US), and Beam Therapeutics Inc. (US), Caribou Biosciences, Inc. (US), OriGene Technologies (US), New England Biolabs (US), Inscripta (US), and Mammoth Biosciences (US).

This research report categorizes the gene editing market into the following segments:

Product & Service

  • Reagents & Consumables
  • Software & Systems
  • Services

Technology

  • CRISPR
  • TALEN
  • ZFN
  • ANTISENSE
  • Other technologies

Application

  • Cell Line Engineering
  • Genetic Engineering
  • Drug Discovery & Development
  • Other Applications

End User

  • Pharmaceutical and Biotechnology Companies
  • Academic and Research Institutes
  • Other End Users

Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • RoE
  • Asia Pacific
    • China
    • India
    • Japan
    • RoAPAC
  • Latin America
    • Brazil
    • RoLATAM
  • Middle East & Africa

Recent Developments of Gene Editing Industry

  • In February 2023, GenScript (China) announced the expansion of its Singapore facility to provide a premium gene synthesis service. This marks a significant expansion of the company’s advanced gene-synthesis capability and enables GenScript to provide the service levels required for novel vaccine and therapeutics development in life sciences.
  • In November 2022, Thermo Fisher Scientific (US) announced the launch of Gibco CTS AAV-MAX Helper-Free AAV Production System, an all-in-one solution suitable for commercial and clinical applications associated with AAV-based gene therapies.
  • In June 2022, Lonza (Switzerland) and Adva entered into a license agreement that will allow Adva to develop innovative solutions for the cell and gene therapies industry.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 30)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS & EXCLUSIONS
    1.3 MARKET SCOPE 
           1.3.1 MARKETS COVERED
    1.4 YEARS CONSIDERED 
    1.5 CURRENCY CONSIDERED 
    1.6 LIMITATIONS 
    1.7 STAKEHOLDERS 
    1.8 SUMMARY OF CHANGES 
 
2 RESEARCH METHODOLOGY (Page No. - 34)
    2.1 RESEARCH DATA 
          FIGURE 1 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
           2.1.2 PRIMARY DATA
                    FIGURE 2 BREAKDOWN OF PRIMARIES: GENE EDITING MARKET
    2.2 MARKET ESTIMATION METHODOLOGY 
          FIGURE 3 GENE EDITING INDUSTRY SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2022
          FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2022
           2.2.1 INSIGHTS FROM PRIMARY EXPERTS
                    FIGURE 5 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
    2.3 MARKET GROWTH RATE PROJECTIONS 
          FIGURE 6 MARKET (SUPPLY-SIDE): CAGR PROJECTIONS
          FIGURE 7 MARKET (DEMAND-SIDE): GROWTH ANALYSIS  OF DEMAND-SIDE DRIVERS
    2.4 DATA TRIANGULATION 
          FIGURE 8 DATA TRIANGULATION METHODOLOGY
    2.5 RESEARCH ASSUMPTIONS 
    2.6 RISK ANALYSIS 
    2.7 RECESSION IMPACT ANALYSIS 
          TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH)
          TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION)
          TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION)
 
3 EXECUTIVE SUMMARY (Page No. - 45)
    FIGURE 9 GENE EDITING MARKET, BY PRODUCT & SERVICE,  2023 VS. 2028 (USD MILLION)
    FIGURE 10 GENE EDITING INDUSTRY, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION)
    FIGURE 11 MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
    FIGURE 12 MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    FIGURE 13 GEOGRAPHICAL SNAPSHOT: MARKET, 2022
 
4 PREMIUM INSIGHTS (Page No. - 49)
    4.1 GENE EDITING MARKET OVERVIEW 
          FIGURE 14 GROWING INVESTMENTS IN GENOMICS RESEARCH TO DRIVE MARKET GROWTH
    4.2 NORTH AMERICA: MARKET,  BY PRODUCT & SERVICE AND COUNTRY (2022) 
          FIGURE 15 REAGENTS & CONSUMABLES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
    4.3 NORTH AMERICA: MARKET, BY APPLICATION,  2023 VS. 2028 (USD MILLION) 
          FIGURE 16 CELL LINE ENGINEERING TO DOMINATE NORTH AMERICAN MARKET
 
5 MARKET OVERVIEW (Page No. - 51)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 17 MARKET DYNAMICS: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
          TABLE 4 GENOME EDITING MARKET: IMPACT ANALYSIS
           5.2.1 DRIVERS
                    5.2.1.1 Rising government funding and number of genomics projects
                    5.2.1.2 Growing applications of genomics
                    5.2.1.3 Introduction of CRISPR-Cas9
           5.2.2 RESTRAINTS
                    5.2.2.1 Off-target effects of CRISPR technology
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Extensive use of genome editing in personalized medicine
                    5.2.3.2 Expanding pipeline for gene therapy
           5.2.4 CHALLENGES
                    5.2.4.1 High equipment costs
    5.3 TECHNOLOGY ANALYSIS 
    5.4 SUPPLY AND VALUE CHAIN ANALYSIS 
           5.4.1 GENE EDITING INDUSTRY: SUPPLY CHAIN ANALYSIS
                    FIGURE 18 GENE EDITING MARKET: SUPPLY CHAIN ANALYSIS
           5.4.2 VALUE CHAIN ANALYSIS
                    FIGURE 19 MARKET: VALUE CHAIN ANALYSIS
    5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 
          FIGURE 20 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
    5.6 PRICING ANALYSIS 
          TABLE 5 AVERAGE SELLING PRICES, BY PRODUCT (KEY PLAYER OFFERINGS)
    5.7 REGULATORY ANALYSIS 
           5.7.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    TABLE 6 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    TABLE 7 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    TABLE 8 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    TABLE 9 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    TABLE 10 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    5.8 ECOSYSTEM ANALYSIS 
          FIGURE 21 MARKET: ECOSYSTEM ANALYSIS
    5.9 PORTER’S FIVE FORCES ANALYSIS 
          TABLE 11 MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.9.1 THREAT OF NEW ENTRANTS
           5.9.2 THREAT OF SUBSTITUTES
           5.9.3 BARGAINING POWER OF BUYERS
           5.9.4 BARGAINING POWER OF SUPPLIERS
           5.9.5 INTENSITY OF COMPETITIVE RIVALRY
    5.10 KEY CONFERENCES AND EVENTS IN 2023 
           TABLE 12 MARKET: CONFERENCES AND EVENTS (2023)
    5.11 KEY STAKEHOLDERS AND BUYING CRITERIA 
           5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS
                     FIGURE 22 MARKET: INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS
           5.11.2 MARKET: BUYING CRITERIA
                     FIGURE 23 KEY BUYING CRITERIA FOR GENE EDITING
    5.12 PATENT ANALYSIS 
           FIGURE 24 PATENTS GRANTED, JANUARY 2011–JUNE 2023
           FIGURE 25 TOP PATENT APPLICANTS, JANUARY 2011–JUNE 2023
 
6 GENE EDITING MARKET, BY PRODUCT & SERVICE (Page No. - 71)
    6.1 INTRODUCTION 
          TABLE 13 GENE EDITING INDUSTRY, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
    6.2 REAGENTS & CONSUMABLES 
           6.2.1 REAGENTS & CONSUMABLES TO HOLD LARGEST MARKET SHARE
                    TABLE 14 GENE EDITING REAGENTS & CONSUMABLES MARKET, BY REGION,  2021–2028 (USD MILLION)
                    TABLE 15 NORTH AMERICA: GENE EDITING REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 16 EUROPE: GENE EDITING REAGENTS & CONSUMABLES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 17 ASIA PACIFIC: GENE EDITING REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 18 LATIN AMERICA: GENE EDITING REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    6.3 SOFTWARE & SYSTEMS 
           6.3.1 INCREASING APPLICATIONS OF GENOME EDITING/SEQUENCING TO BOOST DEMAND FOR SYSTEMS AND SOFTWARE
                    TABLE 19 GENE EDITING SOFTWARE & SYSTEMS MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 20 NORTH AMERICA: GENE EDITING SOFTWARE & SYSTEMS MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 21 EUROPE: GENE EDITING SOFTWARE & SYSTEMS MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 22 ASIA PACIFIC: GENE EDITING SOFTWARE & SYSTEMS MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 23 LATIN AMERICA: GENE EDITING SOFTWARE & SYSTEMS MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
    6.4 SERVICES 
           6.4.1 RISING DEMAND FOR SERVICES TO SUPPORT GROWTH
                    TABLE 24 GENE EDITING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 25 NORTH AMERICA: GENE EDITING SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 26 EUROPE: GENE EDITING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 27 ASIA PACIFIC: GENE EDITING SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 28 LATIN AMERICA: GENE EDITING SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
 
7 GENE EDITING MARKET, BY TECHNOLOGY (Page No. - 79)
    7.1 INTRODUCTION 
          TABLE 29 GENE EDITING INDUSTRY, BY TECHNOLOGY, 2021–2028 (USD MILLION)
    7.2 CRISPR 
           7.2.1 EASE OF USE TO BOOST DEMAND OVER OTHER TECHNOLOGIES
                    TABLE 30 MARKET FOR CRISPR, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 31 NORTH AMERICA: MARKET FOR CRISPR, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 32 EUROPE: MARKET FOR CRISPR, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 33 ASIA PACIFIC: MARKET FOR CRISPR, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 34 LATIN AMERICA: MARKET FOR CRISPR, BY COUNTRY,  2021–2028 (USD MILLION)
    7.3 TALEN 
           7.3.1 ABILITY TO MAKE QUICK MODIFICATIONS TO DRIVE USAGE
                    TABLE 35 MARKET FOR TALEN, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 36 NORTH AMERICA: MARKET FOR TALEN, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 37 EUROPE: MARKET FOR TALEN, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 38 ASIA PACIFIC: MARKET FOR TALEN, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 39 LATIN AMERICA: MARKET FOR TALEN, BY COUNTRY,  2021–2028 (USD MILLION)
    7.4 ZFN 
           7.4.1 UTILITY IN EUKARYOTE CELL STUDIES TO DRIVE MARKET GROWTH
                    TABLE 40 MARKET FOR ZFN, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 41 NORTH AMERICA: MARKET FOR ZFN, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 42 EUROPE: MARKET FOR ZFN, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 43 ASIA PACIFIC: MARKET FOR ZFN, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 44 LATIN AMERICA: MARKET FOR ZFN, BY COUNTRY,  2021–2028 (USD MILLION)
    7.5 ANTISENSE 
           7.5.1 INCREASED APPLICATION IN ENGINEERING HUMAN CELLS FOR DISEASE STUDY TO DRIVE MARKET GROWTH
                    TABLE 45 MARKET FOR ANTISENSE, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 46 NORTH AMERICA: MARKET FOR ANTISENSE, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 47 EUROPE: MARKET FOR ANTISENSE, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 48 ASIA PACIFIC: MARKET FOR ANTISENSE, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 49 LATIN AMERICA: MARKET FOR ANTISENSE, BY COUNTRY,  2021–2028 (USD MILLION)
    7.6 OTHER TECHNOLOGIES 
          TABLE 50 MARKET FOR OTHER TECHNOLOGIES, BY REGION,  2021–2028 (USD MILLION)
          TABLE 51 NORTH AMERICA: MARKET FOR OTHER TECHNOLOGIES,  BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 52 EUROPE: MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY,  2021–2028 (USD MILLION)
          TABLE 53 ASIA PACIFIC: MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY,  2021–2028 (USD MILLION)
          TABLE 54 LATIN AMERICA: MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY,  2021–2028 (USD MILLION)
 
8 GENE EDITING MARKET, BY APPLICATION (Page No. - 91)
    8.1 INTRODUCTION 
          TABLE 55 GENE EDITING INDUSTRY, BY APPLICATION, 2021–2028 (USD MILLION)
    8.2 CELL LINE ENGINEERING 
           8.2.1 INCREASING RESEARCH APPLICATIONS TO PROMOTE MARKET GROWTH
                    TABLE 56 MARKET FOR CELL LINE ENGINEERING, BY REGION,  2021–2028 (USD MILLION)
                    TABLE 57 NORTH AMERICA: MARKET FOR CELL LINE ENGINEERING, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 58 EUROPE: MARKET FOR CELL LINE ENGINEERING, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 59 ASIA PACIFIC: MARKET FOR CELL LINE ENGINEERING, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 60 LATIN AMERICA: MARKET FOR CELL LINE ENGINEERING, BY COUNTRY, 2021–2028 (USD MILLION)
    8.3 GENETIC ENGINEERING 
           8.3.1 GROWING USE OF ANIMAL SIMULATION MODELS IN RESEARCH AND INCREASING INTEREST IN GM CROPS TO DRIVE MARKET
                    TABLE 61 MARKET FOR GENETIC ENGINEERING, BY REGION,  2021–2028 (USD MILLION)
                    TABLE 62 NORTH AMERICA: MARKET FOR GENETIC ENGINEERING, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 63 EUROPE: MARKET FOR GENETIC ENGINEERING, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 64 ASIA PACIFIC: MARKET FOR GENETIC ENGINEERING, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 65 LATIN AMERICA: MARKET FOR GENETIC ENGINEERING,  BY COUNTRY, 2021–2028 (USD MILLION)
    8.4 DRUG DISCOVERY & DEVELOPMENT 
           8.4.1 GROWING RESEARCH AND APPLICATIONS IN DRUG DISCOVERY & DEVELOPMENT TO BOOST GROWTH
                    TABLE 66 MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION,  2021–2028 (USD MILLION)
                    TABLE 67 NORTH AMERICA: MARKET FOR DRUG DISCOVERY & DEVELOPMENT,  BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 68 EUROPE: MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 69 ASIA PACIFIC: MARKET FOR DRUG DISCOVERY & DEVELOPMENT,  BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 70 LATIN AMERICA: MARKET FOR DRUG DISCOVERY & DEVELOPMENT,  BY COUNTRY, 2021–2028 (USD MILLION)
    8.5 OTHER APPLICATIONS 
          TABLE 71 MARKET FOR OTHER APPLICATIONS, BY REGION,  2021–2028 (USD MILLION)
          TABLE 72 NORTH AMERICA: MARKET FOR OTHER APPLICATIONS,  BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 73 EUROPE: MARKET FOR OTHER APPLICATIONS, BY COUNTRY,  2021–2028 (USD MILLION)
          TABLE 74 ASIA PACIFIC: MARKET FOR OTHER APPLICATIONS, BY COUNTRY,  2021–2028 (USD MILLION)
          TABLE 75 LATIN AMERICA: MARKET FOR OTHER APPLICATIONS, BY COUNTRY,  2021–2028 (USD MILLION)
 
9 GENE EDITING MARKET, BY END USER (Page No. - 102)
    9.1 INTRODUCTION 
          TABLE 76 MARKET, BY END USER, 2021–2028 (USD MILLION)
    9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 
           9.2.1 PHARMA & BIOTECH COMPANIES TO HOLD LARGEST MARKET SHARE
                    TABLE 77 MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES,  BY REGION, 2021–2028 (USD MILLION)
                    TABLE 78 NORTH AMERICA: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 79 EUROPE: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 80 ASIA PACIFIC: MARKET FOR PHARMACEUTICAL COMPANIES,  BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 81 LATIN AMERICA: MARKET FOR PHARMACEUTICAL COMPANIES,  BY COUNTRY, 2021–2028 (USD MILLION)
    9.3 ACADEMIC & RESEARCH INSTITUTES 
           9.3.1 TREND OF COLLABORATIVE RESEARCH TO SUPPORT MARKET GROWTH
                    TABLE 82 MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION,  2021–2028 (USD MILLION)
                    TABLE 83 NORTH AMERICA: MARKET FOR ACADEMIC & RESEARCH INSTITUTES,  BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 84 EUROPE: MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 85 ASIA PACIFIC: MARKET FOR ACADEMIC & RESEARCH INSTITUTES,  BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 86 LATIN AMERICA: MARKET FOR ACADEMIC & RESEARCH INSTITUTES,  BY COUNTRY, 2021–2028 (USD MILLION)
    9.4 OTHER END USERS 
          TABLE 87 MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION)
          TABLE 88 NORTH AMERICA: MARKET FOR OTHER END USERS, BY COUNTRY,  2021–2028 (USD MILLION)
          TABLE 89 EUROPE: MARKET FOR OTHER END USERS, BY COUNTRY,  2021–2028 (USD MILLION)
          TABLE 90 ASIA PACIFIC: MARKET FOR OTHER END USERS, BY COUNTRY,  2021–2028 (USD MILLION)
          TABLE 91 LATIN AMERICA: MARKET FOR OTHER END USERS, BY COUNTRY,  2021–2028 (USD MILLION)
 
10 GENE EDITING MARKET, BY REGION (Page No. - 110)
     10.1 INTRODUCTION 
             TABLE 92 GENE EDITING INDUSTRY, BY REGION, 2021–2028 (USD MILLION)
     10.2 NORTH AMERICA 
             10.2.1 NORTH AMERICA: RECESSION IMPACT
                        FIGURE 26 NORTH AMERICA: GENE EDITING MARKET SNAPSHOT
                                      TABLE 93 NORTH AMERICA: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                      TABLE 94 NORTH AMERICA: MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)
                                      TABLE 95 NORTH AMERICA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 96 NORTH AMERICA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 97 NORTH AMERICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.2.2 US
                        10.2.2.1 Robust investment to drive market growth
                                      TABLE 98 US: GENE EDITING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 99 US: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 100 US: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 101 US: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.2.3 CANADA
                        10.2.3.1 Availability of research funding to support growth
                                      TABLE 102 CANADA: GENE EDITING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 103 CANADA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 104 CANADA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 105 CANADA: GENE EDITING INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
     10.3 EUROPE 
             10.3.1 EUROPE: RECESSION IMPACT
                        TABLE 106 EUROPE: GENE EDITING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 107 EUROPE: MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                        TABLE 108 EUROPE: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                        TABLE 109 EUROPE: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 110 EUROPE: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.2 GERMANY
                        10.3.2.1 Strong academic base and rising awareness to boost market
                                      TABLE 111 GERMANY: GENE EDITING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 112 GERMANY: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 113 GERMANY: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 114 GERMANY: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.3 UK
                        10.3.3.1 Government support to boost market growth
                                      TABLE 115 UK: GENE EDITING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 116 UK: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 117 UK: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 118 UK: GENE EDITING INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
             10.3.4 FRANCE
                        10.3.4.1 Government funding for genomics and rising research investments to propel market
                                      TABLE 119 FRANCE: GENE EDITING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 120 FRANCE: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 121 FRANCE: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 122 FRANCE: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.5 ITALY
                        10.3.5.1 Increasing collaborations to drive genomic medicine research and favor market
                                      TABLE 123 ITALY: GENE EDITING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 124 ITALY: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 125 ITALY: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 126 ITALY: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.6 SPAIN
                        10.3.6.1 Proactive research funding to boost market
                                      TABLE 127 SPAIN: GENE EDITING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 128 SPAIN: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 129 SPAIN: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 130 SPAIN: GENE EDITING INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
             10.3.7 REST OF EUROPE
                        TABLE 131 REST OF EUROPE: GENE EDITING MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)
                        TABLE 132 REST OF EUROPE: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                        TABLE 133 REST OF EUROPE: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 134 REST OF EUROPE: MARKET, BY END USER, 2021–2028 (USD MILLION)
     10.4 ASIA PACIFIC 
             10.4.1 ASIA PACIFIC: RECESSION IMPACT
                        FIGURE 27 ASIA PACIFIC: GENE EDITING MARKET SNAPSHOT
                                      TABLE 135 ASIA PACIFIC: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                      TABLE 136 ASIA PACIFIC: MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)
                                      TABLE 137 ASIA PACIFIC: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 138 ASIA PACIFIC: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 139 ASIA PACIFIC: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.4.2 CHINA
                        10.4.2.1 China to hold largest share of APAC market
                                      TABLE 140 CHINA: GENE EDITING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 141 CHINA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 142 CHINA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 143 CHINA: GENE EDITING INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
             10.4.3 JAPAN
                        10.4.3.1 Focus on cancer research to showcase favorable scenarios for gene editing market
                                      TABLE 144 JAPAN: MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 145 JAPAN: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 146 JAPAN: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 147 JAPAN: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.4.4 INDIA
                        10.4.4.1 Growing startups and government support to boost growth potential
                                      TABLE 148 INDIA: GENE EDITING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 149 INDIA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 150 INDIA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 151 INDIA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.4.5 REST OF ASIA PACIFIC
                        TABLE 152 REST OF ASIA PACIFIC: GENE EDITING MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)
                        TABLE 153 REST OF ASIA PACIFIC: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                        TABLE 154 REST OF ASIA PACIFIC: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                        TABLE 155 REST OF ASIA PACIFIC: GENE EDITING INDUSTRY, BY END USER,  2021–2028 (USD MILLION)
     10.5 LATIN AMERICA 
             10.5.1 LATIN AMERICA: RECESSION IMPACT
                        TABLE 156 LATIN AMERICA: GENE EDITING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 157 LATIN AMERICA: MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)
                        TABLE 158 LATIN AMERICA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                        TABLE 159 LATIN AMERICA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 160 LATIN AMERICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.5.2 BRAZIL
                        10.5.2.1 Brazil to dominate Latin American market
                                      TABLE 161 BRAZIL: GENE EDITING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 162 BRAZIL: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 163 BRAZIL: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 164 BRAZIL: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.5.3 REST OF LATIN AMERICA
                        TABLE 165 REST OF LATIN AMERICA: GENE EDITING MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)
                        TABLE 166 REST OF LATIN AMERICA: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                        TABLE 167 REST OF LATIN AMERICA: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                        TABLE 168 REST OF LATIN AMERICA: MARKET, BY END USER,  2021–2028 (USD MILLION)
             10.5.4 MIDDLE EAST & AFRICA
                        10.5.4.1 Increasing adoption of genetic testing to propel market
             10.5.5 MIDDLE EAST & AFRICA: RECESSION IMPACT
                        TABLE 169 MIDDLE EAST & AFRICA: GENE EDITING MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)
                        TABLE 170 MIDDLE EAST & AFRICA: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                        TABLE 171 MIDDLE EAST & AFRICA: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                        TABLE 172 MIDDLE EAST & AFRICA: GENE EDITING INDUSTRY, BY END USER,  2021–2028 (USD MILLION)
 
11 COMPETITIVE LANDSCAPE (Page No. - 149)
     11.1 OVERVIEW 
     11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 
             FIGURE 28 KEY PLAYER STRATEGIES, 2020–2023
     11.3 MARKET SHARE ANALYSIS 
             TABLE 173 GENE EDITING MARKET: DEGREE OF COMPETITION
     11.4 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 
             FIGURE 30 REVENUE ANALYSIS OF TOP FOUR MARKET PLAYERS (2020–2022)
     11.5 COMPANY EVALUATION QUADRANT, 2022 
             11.5.1 STARS
             11.5.2 EMERGING LEADERS
             11.5.3 PERVASIVE PLAYERS
             11.5.4 EMERGING COMPANIES
                        FIGURE 31 GENE EDITING INDUSTRY: COMPANY EVALUATION QUADRANT, 2022
     11.6 COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2022 
             11.6.1 PROGRESSIVE COMPANIES
             11.6.2 STARTING BLOCKS
             11.6.3 RESPONSIVE COMPANIES
             11.6.4 DYNAMIC COMPANIES
                        FIGURE 32 GENE EDITING INDUSTRY: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2022
     11.7 COMPANY FOOTPRINT ANALYSIS 
             11.7.1 PRODUCT/SERVICE FOOTPRINT ANALYSIS
                        TABLE 174 PRODUCT/SERVICE FOOTPRINT ANALYSIS: GENE EDITING INDUSTRY (2022)
             11.7.2 GEOGRAPHIC FOOTPRINT ANALYSIS
                        TABLE 175 GEOGRAPHIC FOOTPRINT ANALYSIS: GENE EDITING MARKET (2022)
     11.8 COMPETITIVE SCENARIO 
 
12 COMPANY PROFILES (Page No. - 161)
     12.1 KEY COMPANIES 
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
             12.1.1 THERMO FISHER SCIENTIFIC
                        TABLE 176 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW
                        FIGURE 33 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2022)
             12.1.2 MERCK KGAA
                        TABLE 177 MERCK KGAA: BUSINESS OVERVIEW
                        FIGURE 34 MERCK KGAA: COMPANY SNAPSHOT (2022)
             12.1.3 GENSCRIPT
                        TABLE 178 GENSCRIPT: BUSINESS OVERVIEW
                        FIGURE 35 GENSCRIPT: COMPANY SNAPSHOT (2022)
             12.1.4 AGILENT TECHNOLOGIES
                        TABLE 179 AGILENT TECHNOLOGIES: BUSINESS OVERVIEW
                        FIGURE 36 AGILENT TECHNOLOGIES: COMPANY SNAPSHOT (2022)
             12.1.5 PERKINELMER
                        TABLE 180 PERKINELMER: BUSINESS OVERVIEW
                        FIGURE 37 PERKINELMER: COMPANY SNAPSHOT (2022)
             12.1.6 LONZA
                        TABLE 181 LONZA: BUSINESS OVERVIEW
                        FIGURE 38 LONZA: COMPANY SNAPSHOT (2022)
             12.1.7 TECAN LIFE SCIENCES
                        TABLE 182 TECAN LIFESCIENCES: BUSINESS OVERVIEW
                        FIGURE 39 TECAN LIFESCIENCES: COMPANY SNAPSHOT (2022)
             12.1.8 SANGAMO THERAPEUTICS
                        TABLE 183 SANGAMO THERAPEUTICS: BUSINESS OVERVIEW
                        FIGURE 40 SANGAMO THERAPEUTICS: COMPANY SNAPSHOT (2022)
             12.1.9 EDITAS MEDICINE
                        TABLE 184 EDITAS MEDICINE: BUSINESS OVERVIEW
                        FIGURE 41 EDITAS MEDICINE: COMPANY SNAPSHOT (2022)
             12.1.10 CRISPR THERAPEUTICS AG
                        TABLE 185 CRISPR THERAPEUTICS AG: BUSINESS OVERVIEW
                        FIGURE 42 CRISPR THERAPEUTICS AG: COMPANY SNAPSHOT (2022)
             12.1.11 PRECISION BIOSCIENCES
                        TABLE 186 PRECISION BIOSCIENCES: BUSINESS OVERVIEW
                        FIGURE 43 PRECISION BIOSCIENCES: COMPANY SNAPSHOT (2020)
             12.1.12 CELLECTIS S.A.
                        TABLE 187 CELLECTIS: BUSINESS OVERVIEW
                        FIGURE 44 CELLECTIS: COMPANY SNAPSHOT (2022)
             12.1.13 INTELLIA THERAPEUTICS
                        TABLE 188 INTELLIA THERAPEUTICS: BUSINESS OVERVIEW
                        FIGURE 45 INTELLIA THERAPEUTICS: COMPANY SNAPSHOT (2022)
             12.1.14 BLUEBIRD BIO INC.
                        TABLE 189 BLUEBIRD BIO: BUSINESS OVERVIEW
                        FIGURE 46 BLUEBIRD BIO: COMPANY SNAPSHOT (2022)
             12.1.15 REGENERON PHARMACEUTICALS INC.
                        TABLE 190 REGENERON PHARMACEUTICALS: BUSINESS OVERVIEW
                        FIGURE 47 REGENERON PHARMACEUTICALS: COMPANY SNAPSHOT (2022)
             12.1.16 AMSBIO
                        TABLE 191 AMSBIO: BUSINESS OVERVIEW
             12.1.17 CREATIVE BIOGENE
                        TABLE 192 CREATIVE BIOGENE: BUSINESS OVERVIEW
             12.1.18 SYNTHEGO CORPORATION
                        TABLE 193 SYNTHEGO CORPORATION: BUSINESS OVERVIEW
             12.1.19 BEAM THERAPEUTICS
                        TABLE 194 BEAM THERAPEUTICS: BUSINESS OVERVIEW
                        FIGURE 48 BEAM THERAPEUTICS: COMPANY SNAPSHOT (2022)
     12.2 OTHER PLAYERS 
             12.2.1 CARIBOU BIOSCIENCES
             12.2.2 ORIGENE TECHNOLOGIES
             12.2.3 NEW ENGLAND BIOLABS
             12.2.4 INSCRIPTA
             12.2.5 MAMMOTH BIOSCIENCES
 
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
 
13 APPENDIX (Page No. - 210)
     13.1 DISCUSSION GUIDE 
     13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’  SUBSCRIPTION PORTAL 
     13.3 CUSTOMIZATION OPTIONS 
     13.4 RELATED REPORTS 
     13.5 AUTHOR DETAILS 

This study involved four major activities in estimating the current size of the gene editing market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments.

Secondary Research

Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the gene editing market. The secondary sources used for this study include publications from government sources such as International Chromosome and Genome Society (ICGS), the National Human Genome Research Institute (NHGRI), the Asia Pacific Society of Human Genetics (APSHG), the Genetics Society of America (GSA), the European Society of Human Genetics (ESHG), Centers for Common Disease Genomics (CDDG), Centre for Cellular & Molecular Biology (CCMB) (India), and the Department of Biotechnology (DBT) (India), Annual Reports, SEC Fillings, Press Releases, Investor Presentation, Expert Interviews, and MarketsandMarkets Analysis. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

Primary Research

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information.

Gene Editing Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the gene editing market. These methods were also used extensively to estimate the size of various segments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and markets have been identified through extensive secondary research
  • The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Gene Editing Market Size, and Share

Data Triangulation

After arriving at the overall market size—using the market size estimation processes—the market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics of each market segments, the data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the gene editing industry.

Market Definition

Gene editing or genome engineering is the insertion, deletion, or replacement of DNA at a specific site in the genome of an organism or cell. It is usually achieved in the lab using genome-editing tools, such as CRISPR, TALEN, and ZFN. This emerging and rapidly evolving field enables the efficient and directed modification of cell lines and genomes of animals and plants.

Key Stakeholders

  • Genome editing/genome engineering product manufacturers
  • Suppliers and distributors of genomic instruments/systems and consumables
  • Contract manufacturing organizations
  • Pharmaceutical and biotechnology companies
  • Diagnostic centers and medical colleges
  • Contract research organizations
  • Government associations and research institutes
  • Healthcare associations/institutes
  • Regulatory authorities
  • Business research firms

Report Objectives

  • To define, describe, and forecast the gene editing market based on technology, product & service, application, end user, and region
  • To provide detailed information about the drivers, restraints, opportunities, and challenges influencing the market growth
  • To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall gene editing market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of market segments in North America, Europe, the Asia Pacific (APAC), Latin America (LATAM), and the Middle East & Africa (MEA)
  • To profile the key players and comprehensively analyze their core competencies2 in terms of key developments, product portfolios, and financials
  • To track and analyze competitive developments, such as product/service launches, partnerships, collaborations, agreements, and acquisitions, in the gene editing market

Micromarkets are the further segments and subsegments of the gene editing market.

Core competencies of companies are captured in terms of the key developments, market shares, and key strategies adopted to sustain their positions in the market.

Available Customizations:

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

  • Company Information: Detailed analysis and profiling of additional market players (up to five)
  • Geographic Analysis:  Further breakdown of the RoE gene editing market, by country. Further breakdown of the RoAPAC gene editing market, by country. Further breakdown of the RoLATAM and MEA gene editing markets, by country.
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
BT 3380
Published ON
Jul, 2023
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Gene Editing Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback